Geron Stock Doubles After Imetelstat Receives FDA Panel Approval

Key PointsGeron is a biotechnology company specializing in cell therapies to treat various blood cancers.The FDA Advisory Committee voted 12 to 2 in favor of approving Imetelstat, Geron's lead product for treating transfusion-dependent anemia among myelodysplastic syndrome (MDS) patients.The FDA has an action date of June 16, 2023, to make a final decision.5 stocks we like better than GeronGeron Inc. NASDAQ: GERN is a clinical-stage biotech in the medical sector focused on developing cell therapies to treat ...